

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG  
Form 6-K  
July 17, 2003

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated July 16, 2003  
(Commission File No. 1-15024)

-----  
Novartis AG  
(Name of Registrant)

-----  
Lichtstrasse 35  
4056 Basel  
Switzerland

-----  
(Address of Principal Executive Offices)  
-----

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F:  Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes:  No:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes:  No:

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes:  No:

Enclosures: Novartis IR invitation to the Novartis Half Year Sales & Results 2003 Conference Call

Edgar Filing: NOVARTIS AG - Form 6-K

Investor Relations

Novartis International AG  
CH-4002 Basel  
Switzerland

[LOGO] NOVARTIS

Novartis Corporation  
608 Fifth Avenue  
New York, NY 10020  
USA

- Investor Relations Invitation -

Half Year Sales & Results 2003 Conference Call

Dear Investor,

We are pleased to invite you to our Half Year Sales & Results 2003 Conference Call. Please find below the dial-in details:

Date: Monday, July 21st, 2003

Time: 06.00 p.m. Switzerland  
05.00 p.m. UK  
12.00 p.m. New York

Advisable: dial-in 10 minutes before

Phone numbers: +41 91 610 56 00 Europe and ROW  
+800 2467 8700 Toll free Europe and ROW  
+44 207 866 4111 UK  
+1800 860 2442 Toll free USA and Japan  
+1 866 519 5086 Toll free Canada  
+1 866 519 5087 Toll free Mexico

You may access the conference call as a live audio webcast on the Internet on July 21st: <http://www.novartis.com/investors>.

Additional financial information will be available on Monday, July 21st, on the Internet <http://www.novartis.com/investors>

Edgar Filing: NOVARTIS AG - Form 6-K

Playback for 48 hours, starting

Date: Monday, July 21st, 2003

Time: 09.00 p.m. Switzerland  
08.00 p.m. UK  
03.00 p.m. New York

Phone numbers: +41 91 612 4330 Europe and ROW  
+44 207 866 4300 UK  
+1 877 344 7529 US

Dial-in code: 431 (followed by the # sign)

###

Novartis Global Investor Relations

-----

Karen J. Huebscher, Ph.D. +41 61 324 84 33  
karen.huebscher@group.novartis.com

Nafida Bendali +41 61 324 35 14  
nafida.bendali@group.novartis.com

Katharina Furrer +41 61 324 53 16  
katharina.furrer@group.novartis.com

Alex Kelly +41 61 324 62 89  
alex.kelly@group.novartis.com

Sean Wells +41 324 33 34  
sean.wells@group.novartis.com

Silke Zentner +41 61 324 86 12  
silke.zentner@group.novartis.com

Fax: +41 61 324 84 44  
www.novartis.com

Novartis North America Investor Relations

-----

Kamran Tavangar, Ph.D. +1 212 830 24 33  
kamran.tavangar@group.novartis.com

John Menditto +1 212 830 24 44  
john.menditto@group.novartis.com

Sabine Moravi +1 212 830 24 56  
sabine.moravi@group.novartis.com

Jill Pozarek +1 212 830 24 45  
jill.pozarek@group.novartis.com

Fax: +1 212 830 24 05  
www.novartis.com

Edgar Filing: NOVARTIS AG - Form 6-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Novartis AG has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NOVARTIS AG

Date: July 17, 2003

By: /s/ MALCOLM CHEETHAM  
-----

Name: Malcolm Cheetham  
Title: Head Group Financial Reporting  
and Accounting

Page 4 of 4 Total Pages